Pertuzumab, an inhibitor of heterodimerization of ERBB2 (erb-b2 receptor tyrosine kinase 2, commonly known as HER-2 and HER-2/neu) with other ERBB receptor family members, is the first agent granted accelerated approval for the neoadjuvant treatment of high-risk early stage breast cancer based on pCR data [3]. Here, ERBB2 is linked to breast cancer.